Radiopharm Theranostics partners with Siemens Healthineers to manufacture, distribute RAD101 doses for US Phase 3 trial

Rite Aid Corporation

Rite Aid Corporation

RAD

0.00
  • Radiopharm Theranostics partnered with Siemens Healthineers to manufacture and distribute 18F-labeled RAD101 doses for a planned U.S. Phase 3 pivotal trial.
  • Collaboration follows Phase 2b results showing 93% concordance between RAD101 PET and MRI across evaluable lesions.
  • Radiopharm targets Phase 3 initiation in Q4 2026; RAD101 holds FDA Fast Track designation for recurrent brain metastases imaging.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Radiopharm Theranostics Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202607220700PRIMZONEFULLFEED1001213823) on July 22, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.